About Herceptin
Herceptin (trastuzumab) is a humanised monoclonal antibody designed to specifically target HER2, whose overexpression/gene amplification is an adverse prognostic factor in breast cancer. By activating the immune system and suppressing HER2, Herceptin delivers high cure rates for women with HER2-positive early breast cancer and extends survival for women with HER2-positive metastatic disease. Therefore, Herceptin is now firmly established as the foundation of care for women with HER2 positive breast cancer across all stages of the disease.